Kate raises the bar for DMD gene therapy

As patients and the biopharma industry await an FDA decision on full approval of the first gene therapy to reach the market for Duchenne muscular dystrophy, new data from Kate Therapeutics bolsters the central thesis of many gene therapy start-ups: that engineering AAV vectors to be more targeted will dramatically improve on first-generation products.

On Friday, Kate Therapeutics Inc. co-founder and CSO Sharif Tabebordbar will present preclinical data from the company’s lead internal development candidate, KT809, during a plenary session at the American Society of Gene & Cell Therapy (ASGCT), which runs through May 11...